| DCAPI1049 |
Lomustine (CeeNU) |
Lomustine (CeeNU) |
|
| DC7455 |
Lonafarnib
Featured
|
Lonafarnib(Sch66336) is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM, respectively. |
|
| DCAPI1199 |
Lonidamine
Featured
|
Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis. |
|
| DC9168 |
Loperamide HCl |
Loperamide HCl is an opioid-receptor agonist used as long-acting synthetic antidiarrheals. |
|
| DC8907 |
Lopinavir
Featured
|
Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC21250 |
Lopixibat chloride |
Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).. |
|
| DC9104 |
Loratadine |
Loratadine(SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. |
|
| DC1011 |
Lorcaserin
Featured
|
Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. |
|
| DC8644 |
Lorcaserin Hydrochloride
Featured
|
Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. |
.png)
|
| DC8645 |
Lorcaserin hydrochloride heMihydrate |
Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. |
|
| DC8642 |
Lorediplon
Featured
|
Lorediplon is a new GABAA modulator Drug for treatment of insomnia. |
|
| DC10254 |
L-Ornithine |
L-ornithine has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle. |
|
| DC8356 |
Losartan Carboxylic Acid
Featured
|
Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver. |
|
| DCAPI1419 |
Losartan |
Losartan is a potent, non peptide antagonist of the angiotensin II receptor type 1. This receptor initiates a signal cascade that causes vasoconstriction. Antagonism of this receptor in turn causes vasodilation by blocking the signal from angiotensin II. |
|
| DC9153 |
Losartan Potassium
Featured
|
Losartan is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. |
|
| DC7711 |
Losmapimod
Featured
|
Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3. |
|
| DCAPI1355 |
Loteprednol etabonate |
Loteprednol etabonate |
|
| DC2105 |
Lovastatin (MK-803)
Featured
|
Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent). |
|
| DC8066 |
Loxiglumide
Featured
|
Loxiglumide is a Exogenous cholecystokinin (CCK-A) receptor antagonist, stimulates calorie intake and hunger feelings in humans. |
|
| DC22338 |
Larotrectinib (LOXO-101 free base)
Featured
|
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
|
| DC9837 |
Larotrectinib (LOXO-101 sulfate)
Featured
|
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
|
| DC11448 |
LOXO 195(Selitrectinib)
Featured
|
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively. |
|
| DCAPI1565 |
Loxoprofen Sodium |
Loxoprofen is a non-steroidal anti-inflammatory drug that is quickly converted to the trans-alcohol metabolite. It is similar to ibuprofen and naproxen, while also being a Cycloxygenase (COX) inhibitor. |
|
| DC10867 |
LP-211
Featured
|
LP-211 is a selective and blood−brain barrier penetrant 5-HT7 receptor agonist, with a Ki of 0.58 nM, with high selectivity over 5-HT1A receptor (Ki, 188 nM) and D2 receptor (Ki, 142 nM). |
|
| DC23403 |
LP99
Featured
|
LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9. |
|
| DC20000 |
LR-90
Featured
|
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model. |
|
| DC20086 |
LRE1
Featured
|
LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase. |
|
| DC11440 |
LRRK2 inhibitor 18
Featured
|
LRRK2 inhibitor 18(Compound 18) is a potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki of 4.1 nM. |
|
| DC8237 |
LRRK2-IN-1
Featured
|
LRRK2-IN-1 inhibits both wild-type and G2019S mutant LRRK2 kinase activity with IC50 values of 13 nM and 6 nM , respectively with 0.1 mM ATP in the assay. |
|
| DC12514 |
LSD1 inhibitor 24 |
LSD1 inhibitor 24 is a novel potent, selective lysine-specific demethylase 1 (LSD1) inhibitor with IC50 of 1 nM, induces CD11b expression in THP-1 cells with EC50 of 8 nM. |
|
